CPT® Code 86975

Official Description

Pretreatment of serum for use in RBC antibody identification; incubation with drugs, each

Common Language Description

The CPT® Code 86975 refers to the process of pretreating serum for the purpose of identifying red blood cell (RBC) antibodies. This procedure involves the incubation of a blood sample with specific drugs, which is essential for accurately determining the presence of antibodies that may react with red blood cells. In this context, a blood sample is collected and treated with special antigens by introducing red blood cells that have these antigens already attached to a serum derived from the patient's blood. This step is crucial in the laboratory setting, as it helps in the identification of any antibodies that may be present in the serum, which can be significant for various medical conditions, including blood transfusions and organ transplants. It is important to note that there are additional codes related to this procedure that specify different scenarios: CPT® Code 86976 is used when the serum sample is diluted prior to the addition of red blood cells; CPT® Code 86977 is applicable when an inhibitor is introduced to neutralize a drug that may be present in the serum; and CPT® Code 86978 is designated for instances where red blood cells and blood serum are incubated together before the testing process is initiated. Each of these codes serves to provide a more precise description of the laboratory procedures performed, ensuring accurate coding and billing for the services rendered.

1. Indications

The procedure associated with CPT® Code 86975 is indicated for the identification of red blood cell antibodies in patients. This is particularly important in scenarios such as:

Blood Transfusion Compatibility Ensuring that the blood type of a donor is compatible with that of the recipient to prevent adverse reactions during transfusions.
Autoimmune Hemolytic Anemia Diagnosing conditions where the immune system mistakenly attacks red blood cells, leading to their destruction.
Pregnancy Management Monitoring Rh incompatibility between a mother and her fetus, which can lead to hemolytic disease of the newborn.
Organ Transplantation Assessing the risk of antibody-mediated rejection in transplant patients.

2. Procedure

The procedure for CPT® Code 86975 involves several critical steps to ensure accurate identification of RBC antibodies. The first step is the collection of a blood sample from the patient, which is then processed in a laboratory setting. Following the collection, the serum is separated from the blood cells. The next step involves the incubation of this serum with red blood cells that have specific antigens attached. This incubation allows for the interaction between the antibodies present in the serum and the antigens on the red blood cells. The laboratory technician must carefully monitor the incubation conditions, including temperature and duration, to optimize the reaction. After the incubation period, the sample is evaluated for the presence of any antibodies that may have reacted with the red blood cells. This evaluation is crucial for determining the appropriate course of action based on the results, which may include further testing or immediate clinical interventions.

3. Post-Procedure

After the completion of the procedure associated with CPT® Code 86975, the laboratory will analyze the results to identify any antibodies present in the serum. The findings will be documented and reported to the requesting physician, who will interpret the results in the context of the patient's clinical situation. Depending on the outcome, further testing may be required, or the physician may need to take specific actions, such as adjusting transfusion protocols or initiating treatment for autoimmune conditions. It is essential for healthcare providers to communicate the results effectively to ensure that appropriate follow-up care is provided to the patient. Additionally, proper documentation of the procedure and results is necessary for compliance and billing purposes.

Short Descr	RBC SERUM PRETX INCUBJ DRUGS
Medium Descr	PRETX SERUM RBC ANTIBODY INCUBATION DRUGS EACH
Long Descr	Pretreatment of serum for use in RBC antibody identification; incubation with drugs, each
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	STV-Packaged Codes
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T1H - Lab tests - other (non-Medicare fee schedule)
MUE	1
CCS Clinical Classification	235 - Other Laboratory

90	Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.